TW200745041A - Aporphine and oxoaporphine compounds and pharmaceutical use thereof - Google Patents
Aporphine and oxoaporphine compounds and pharmaceutical use thereofInfo
- Publication number
- TW200745041A TW200745041A TW096117667A TW96117667A TW200745041A TW 200745041 A TW200745041 A TW 200745041A TW 096117667 A TW096117667 A TW 096117667A TW 96117667 A TW96117667 A TW 96117667A TW 200745041 A TW200745041 A TW 200745041A
- Authority
- TW
- Taiwan
- Prior art keywords
- ischemic
- diseases
- oxoaporphine
- aporphine
- compounds
- Prior art date
Links
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical class C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 title abstract 4
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 title abstract 2
- XHCICOLGLYLOAA-UHFFFAOYSA-N oxoaporphine Chemical class COC1=C(OC)C=C2C(C(C(OC)=C3)=O)=C4C3=CC=NC4=CC2=C1 XHCICOLGLYLOAA-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 abstract 8
- 208000023589 ischemic disease Diseases 0.000 abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 206010008088 Cerebral artery embolism Diseases 0.000 abstract 1
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010072564 Peripheral artery thrombosis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000037902 enteropathy Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 201000010849 intracranial embolism Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000006492 vascular dysfunction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides aporphine and oxoaporphine compounds that may be used to manufacture a medicaments for preventing or treating vascular dysfunctions that may result in ischemic and metabolic diseases or preventing complications associated with these diseases in human and mammal. The ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc. The metabolic disease may include diabetes-induced vascular diseases, such as hypertension, atherosclerosis, peripheral artery or venous thrombosis, retinopathy and nephropathy. Methods for treating ischemic and metabolic diseases or preventing complications are also disclosed.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2006/001054 WO2007134485A1 (en) | 2006-05-22 | 2006-05-22 | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200745041A true TW200745041A (en) | 2007-12-16 |
Family
ID=38722927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096117667A TW200745041A (en) | 2006-05-22 | 2007-05-17 | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW200745041A (en) |
| WO (1) | WO2007134485A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010026487A1 (en) * | 2008-09-08 | 2010-03-11 | University Of Concepcion | Therapeutic methods and compositions |
| SG190914A1 (en) * | 2010-11-24 | 2013-07-31 | Dong A St Co Ltd | Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same |
| EP2742974A1 (en) * | 2012-12-13 | 2014-06-18 | Valentia Biopharma | Phenanthrene derivatives for use as medicaments |
| CN105315208A (en) * | 2014-07-17 | 2016-02-10 | 中国科学院兰州化学物理研究所 | Aporphine type alkaloid and preparation method thereof |
| CN110772516B (en) * | 2019-12-02 | 2022-10-04 | 四川大学华西医院 | Application of isocorydine or salt thereof in preparing medicine for reducing blood uric acid level and preventing and treating uric acid nephropathy |
| CN111920812B (en) * | 2020-07-10 | 2022-09-20 | 深圳市臻质医疗科技有限公司 | Application of calcium channel inhibitor oxylipine in osteoarthritis |
| CN114948956B (en) * | 2021-02-19 | 2024-01-19 | 海南医学院 | Application of Xinmu Jiang Zijian in preparing medicine for preventing and treating diabetic complications |
| KR20230063451A (en) * | 2021-11-02 | 2023-05-09 | 연세대학교 산학협력단 | Use of Apomorphine as a therapeutic agent for necroptosis-related diseases |
| KR102760018B1 (en) * | 2021-11-15 | 2025-01-23 | 각코우호우진 지치 이카다이가쿠 | Ferrotosis inhibitors and uses thereof |
| CN114751860B (en) * | 2022-03-22 | 2024-03-15 | 华侨大学 | A method for synthesizing nuciferine or its derivatives and nuciferine derivatives and their applications |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4188392A (en) * | 1975-07-16 | 1980-02-12 | The University Of Mississippi | Antimicrobial compositions |
| DE2757335C3 (en) * | 1977-12-22 | 1982-03-25 | Gödecke AG, 1000 Berlin | Process for the O-methylation of hydroxyaporphines |
| US5258384A (en) * | 1991-01-11 | 1993-11-02 | British Technology Group Limited | S-11-hydroxy-10-methylaporphine and its biologically active salt forms as 5HT1A inhibitors |
| CN1566100A (en) * | 2003-06-19 | 2005-01-19 | 美时化学制药股份有限公司 | Apofen and ketoapofen compounds and their medicinal uses |
-
2006
- 2006-05-22 WO PCT/CN2006/001054 patent/WO2007134485A1/en not_active Ceased
-
2007
- 2007-05-17 TW TW096117667A patent/TW200745041A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007134485A1 (en) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200745041A (en) | Aporphine and oxoaporphine compounds and pharmaceutical use thereof | |
| ATE416177T1 (en) | HETARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | |
| MX2010004450A (en) | Bicyclic heterocycle derivatives and methods of use thereof. | |
| WO2010091376A3 (en) | Devices and methods for perfusion therapy | |
| WO2012174338A3 (en) | Method of selecting therapeutic indications | |
| WO2009106991A3 (en) | Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders | |
| MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
| TN2011000228A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| MX2010004074A (en) | Combination 059. | |
| TW200732347A (en) | VEGF analogs and methods of use | |
| SV2011003901A (en) | ARILO COMPOUNDS WITH HETEROCYCLIC SUBSTITUTES AS HIF INHIBITORS | |
| WO2010127099A3 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| IL209282A (en) | N-piperidin-3-yl-2-benzimidazole carboxamide derivatives and medicaments comprising them for treating circulatory diseases | |
| WO2009068214A3 (en) | Heteroaryl-substituted piperidines | |
| WO2015191934A8 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
| WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| WO2008043107A3 (en) | Use of tight junction antagonists to treat inflammatory bowel disease | |
| WO2010121164A3 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| WO2008013986A3 (en) | Compositions and methods for treating or preventing ophthalmic light toxicity | |
| WO2009035634A3 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors | |
| WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
| WO2017011356A3 (en) | Mcj inhibitors for use in treating drug-induced diseases and conditions |